Disease · MONDO_0019434
Comparisons in its trials31
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 31
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ACZ885 Treatment Naive vs ACZ885 Treated: Number of Participants With Anti -ACZ885 Antibodies at Any Visit During the Study | 0 of 123 | 0 of 147 | 270 | NCT00891046 | Trial comparisons |
| ACZ885 Treated vs ACZ885 Treatment Naive: serious adverse events | 47 of 147 | 40 of 123 | 270 | NCT00891046 | Trial comparisons |
| Canakinumab vs Placebo: serious adverse events | 2 of 43 | 2 of 41 | 84 | NCT00886769 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Macrophage Activation Syndrome (MAS). | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Antidrug Antibodies (ADA) Against Anakinra. | 6 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Neutralizing Antibodies. | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With at Least One Serious Adverse Event Including Death. | 0 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With at Least One Adverse Event. | 6 of 6 | 4 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: deaths from any cause | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: serious adverse events | 0 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Responders in Assessment of Physical Function (CHAQ/SHAQ). | 4 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of ACR70 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 5 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of ACR90 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 4 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of ACR50 Responders With Absence of Fever During 7 Days Preceding Week 2. | 6 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of ACR30 Responders With Absence of Fever Attributable to the Disease During the 7 Days Preceding Week 2. | 6 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Inactive Disease. | 3 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of ACR70 Responders With Absence of Fever During 7 Days Preceding Week 2. | 6 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Absence of Fever During the 24 Hours Preceding Week 1. | 6 of 6 | 4 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of ACR30 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 5 of 6 | 3 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Absence of Fever During the 7 Days Preceding Week 2. | 6 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019434/comparisons